Bank of New York Mellon Corp Sells 1,194,538 Shares of Bristol Myers Squibb Company $BMY

Bank of New York Mellon Corp decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 4.9% during the first quarter, HoldingsChannel.com reports. The firm owned 23,301,337 shares of the biopharmaceutical company’s stock after selling 1,194,538 shares during the quarter. Bank of New York Mellon Corp’s holdings in Bristol Myers Squibb were worth $1,413,226,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at $25,000. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Bayban purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 3.1%

Bristol Myers Squibb stock opened at $58.73 on Thursday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The business has a fifty day moving average price of $56.84 and a 200-day moving average price of $57.72. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a market capitalization of $119.94 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 0.16 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.33 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BMY shares. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Cantor Fitzgerald restated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday, July 6th. Bank of America dropped their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Investors are focusing on Bristol Myers Squibb’s strong earnings surprise history, with recent coverage suggesting the company has the right setup to beat estimates again in its next quarterly report. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Analysts highlighted progress in BMY’s CELMoD program, including the FDA filing for mezigdomide in relapsed or refractory multiple myeloma, which could strengthen the company’s oncology portfolio and long-term pipeline value. Can BMY’s CELMoD Program Advancements Strengthen Its Oncology Portfolio?
• Positive Sentiment: Agilent’s FDA approval for a companion diagnostic tied to Bristol Myers Squibb’s Opdivo franchise supports continued relevance for one of BMY’s key cancer drugs. Agilent Receives FDA Approval…
• Neutral Sentiment: BMY has been attracting increased user and market attention, but the coverage does not point to a specific catalyst beyond general interest in the stock. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Wells Fargo initiated/maintained a Hold rating, signaling a cautious but not bearish view that may limit upside enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
• Negative Sentiment: MarketWatch noted that Bristol Myers Squibb underperformed peers in Tuesday trading, suggesting some relative weakness versus other healthcare stocks. Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
• Negative Sentiment: Septa Pharmaceuticals acquired CeeNU (lomustine) from Bristol Myers Squibb Canada, reflecting a divestiture of a legacy oncology asset rather than a growth driver. Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.